Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 23 | -0.66 Decreased by -6.45% | -0.32 Decreased by -332.03% |
| Mar 15, 23 | -0.46 Increased by +25.81% | -0.30 Decreased by -177.78% |
| Nov 10, 22 | -0.51 Increased by +3.77% | -0.64 Increased by +31.74% |
| Aug 11, 22 | -0.61 Decreased by -74.29% | -0.59 Decreased by -5.75% |
| May 12, 22 | -0.62 Decreased by -40.91% | -0.53 Decreased by -32.04% |
| Mar 31, 22 | -0.62 Decreased by -148.00% | -0.60 Decreased by -5.56% |
| Oct 28, 21 | -0.53 Decreased by -112.00% | -0.46 Decreased by -33.08% |
| Aug 5, 21 | -0.35 Increased by +46.97% | -0.38 Increased by +20.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 1.49 M Increased by +36.54% | -82.00 M Decreased by -730.12% | Decreased by -5.50 K% Decreased by -507.97% |
| Dec 31, 22 | 1.47 M Increased by +N/A% | -38.38 M Decreased by -196.27% | Decreased by -2.60 K% Decreased by N/A% |
| Sep 30, 22 | 4.96 M Increased by +105.47% | -14.63 M Decreased by -31.98% | Decreased by -295.22% Increased by +35.77% |
| Jun 30, 22 | 1.61 M Decreased by -57.38% | -17.28 M Decreased by -143.24% | Decreased by -1.07 K% Decreased by -470.67% |
| Mar 31, 22 | 1.09 M Increased by +326.56% | -9.88 M Decreased by -23.41% | Decreased by -904.58% Increased by +71.07% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | -12.96 M Decreased by -220.22% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 2.41 M Increased by +N/A% | -11.09 M Decreased by -4.00% | Decreased by -459.62% Decreased by N/A% |
| Jun 30, 21 | 3.79 M Increased by +N/A% | -7.11 M Decreased by -40.94% | Decreased by -187.52% Decreased by N/A% |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.